Table 1 Characteristics of the TARGET population at baseline stratified by treatment arm
|  | All Patients (n = 122) | MTX + TNF inhibitor (n = 61) | Triple therapy (n = 61) | P-value |
|---|---|---|---|---|
| Â | Â | N (%) or median (interquartile range) | Â | |
Age, years | 57.0 (53.0, 63.0) | 56.0 (53.0, 62.0) | 58.0 (54.0, 63.0) | 0.56 |
Sex, female | 93 (76.2) | 44 (80.3) | 49 (80.3) | 0.28 |
Race | ||||
White | 86 (74.8) | 46 (80.7) | 40 (69.0) | 0.09 |
Black | 18 (15.7) | 9 (15.8) | 9 (15.5) | Â |
Other | 11 (9.6) | 2 (3.5) | 9 (15.5) | Â |
Ethnicity | ||||
Hispanic | 33 (27.0) | 17 (27.9) | 16 (26.2) | 0.83 |
Non-Hispanic | 89 (73.0) | 44 (72.1) | 45 (73.8) | Â |
RA disease duration, years | 1.5 (0.6, 5.9) | 2.5 (0.6, 7.2) | 1.4 (0.5, 5.3) | 0.42 |
Serologic status, positive | 78 (63.9) | 39 (63.9) | 39 (63.9) | 1.00 |
DAS28-CRP | 4.9 (4.0, 5.6) | 5.0 (4.0, 5.5) | 4.8 (4.0, 5.7) | 0.86 |
hsCRP (mg/L) | 4.9 (1.8, 11.3) | 4.9 (1.6, 10.6) | 5.1 (1.8, 11.3) | 0.86 |
Glucocorticoid use | 35 (28.7) | 18 (29.5) | 17 (27.9) | 0.84 |
NSAID use | 47 (38.5) | 30 (49.2) | 17 (27.9) | 0.02 |
Aspirin use | 24 (19.7) | 16 (26.2) | 8 (13.1) | 0.19 |
Methotrexate weekly dose (mg) | 20.0 (15.0, 25.0) | 20.0 (15.0, 25.0) | 20.0 (15.0, 25.0) | 0.15 |
Heath assessment questionnaire | 1.3 (0.6, 1.8) | 1.3 (0.5, 1.9) | 1.4 (0.8, 1.6) | 0.86 |
Body mass index (kg/m2) | 29.6 (26.5, 34.6) | 29.7 (26.2, 34.5) | 29.6 (26.5, 34.7) | 0.99 |
High blood pressure | 47 (38.5) | 24 (39.3) | 23 (37.7) | 0.85 |
Hyperlipidemia | 9 (7.4) | 4 (6.6) | 5 (8.2) | 0.74 |
Diabetes mellitus | 1 (0.8) | 1 (1.6) | 0 | 1.00 |
Tobacco use | ||||
Current | 14 (11.5) | 5 (8.2) | 9 (14.8) | 0.48 |
Past | 27 (22.1) | 15 (24.6) | 12 (19.7) | Â |
Never | 81 (66.4) | 41 (67.2) | 40 (65.6) | Â |